Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF)
is a progressive fibrotic lung disease of unknown cause. It remains incurable and has a poor prognosis for many patients, with a median survival of 3-5 years from diagnosis.
For more information on our current and past study involvement, please follow the links to the left (* indicates Bristol led).
Studies & trials
-
A role for cardiopulmonary exercise testing in detecting physiological changes underlying health
A longitudinal study evaluating the prognostic role of cardiopulmonary exercise testing in patients with IPF. This study has been published.
-
Description of Palliative Care Models in ILD Clinics and their impact on IPF care*
A multi-centre retrospective study comparing novel palliative care models and their impact on IPF care. This study is currently open.
-
The Role of Vascular endothelial growth factor in the development of IPF*
A basic science and translational study examining the biological pathways underpinning the development of IPF. This study has been published.
-
CELGENE
A Phase II randomised placebo controlled multi-centre study of the use of CC-90001 in patients with IPF. This study has completed recruitment but is not yet published.
-
INMARK
A multicentre study of biomarkers of extracellular matrix turnover in IPF. This study has been published
-
Drug to drug interaction in IPF
Open label phase 4 study investigating the pharmacokinetic drug-drug interaction between Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis. This study has been published
-
INSTAGE
Randomised controlled trial investigating combined use of nintedanib and sildenafil compared to nintedanib alone, in patients with IPF. This study has been published
-
GALACTIC
A randomised, double-blind, placebo-controlled phase 2b trial in subjects with IPF investigating the efficacy and safety of TD139. This study has completed recruitment but is not yet published.
-
TIPAL
The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole, a randomised placebo-controlled multi-centre clinical trial.
-
MABEL
A parallel group, double-blind, randomised, placebo-controlled trial comparing the effectiveness and cost effectiveness of low dose oral modified release morphine versus placebo on patient-reported worst breathlessness in people with chronic breathlessness.
